Form 4: Director Herve Hoppenot Receives Maze Therapeutics Options

Director Herve Hoppenot was granted 18,000 stock options in Maze Therapeutics, Inc. as part of a standard equity compensation.

Summary

• Director Herve Hoppenot acquired 18,000 stock options in Maze Therapeutics, Inc. (MAZE).
• The options have an exercise price of $23.58 per share.
• The grant date for the transaction was June 8, 2026.
• The options are scheduled to vest on the earlier of the 2027 annual stockholders meeting or June 8, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's financial outlook.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Vesting is contingent upon the reporting person's continued service to the issuer.

Future Outlook

The options vest in one year, contingent on continued service, indicating a standard retention incentive for board members.

Management Comments

• The option shall vest and be fully exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 8, 2027.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure board alignment with company performance.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical director compensation packages for mid-cap biotechnology firms.

Stakeholder Impact

• Minor dilution impact for shareholders upon future exercise of options.

Next Steps

• Vesting of options on or before June 8, 2027.

Key Dates

Keywords

Maze Therapeutics, MAZE, Form 4, Insider Trading, Stock Options, Director Compensation